2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1067

Incidence and Prevalence Of Systemic Lupus Erythematosus: A 2010 Nation-Wide Population-Based Study Using French National Administrative Databases
Abstract Number: 2760

Incidence and Severity Of Myocardial Infarction In Subjects Receiving Anti Tumour Necrosis Factor Drugs For Rheumatoid Arthritis: Results From Linking the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project
Abstract Number: 97

Incidence and Trend Of Osteoarthritis In An Administrative Database From British Columbia, Canada
Abstract Number: 2362

Incidence Of Adverse Events In Patients With Rheumatoid Arthritis and Spondyloarthritis Exposed To Anti-TNF Therapy. Data From The Brazilian Registry For Monitoring Of Biologic Therapies In Rheumatic Diseases (BiobadaBrasil)
Abstract Number: 1218

Incidence Of and Risk Factors For Clinical Fractures In Patients With Systemic Lupus Erythematosus and Matched Controls: A Population-Based Study In The United Kingdom
Abstract Number: 1080

Incidence Of Coronary Heart Disease Associated With Arthritis: A Canadian Population-Based Cohort Study
Abstract Number: 2360

Incidence Of Diabetes and Effect Of Etanercept and Adalimumab On HbA1c Over 1 Year: Data From a Randomised Trial In Patients With Rheumatoid Arthritis
Abstract Number: 1365

Incidence Of Hepatitis B Virus Reactivation In Patients With Rheumatoid Arthritis During Treatment With Biologics
Abstract Number: 305

Incidence of Herpes Zoster in Patients with Psoriatic Arthritis
Abstract Number: 1037

Incidence Of Malignancy In Patients With Rheumatoid Arthritis From a Japanese Large Observational Cohort (NinJa)
Abstract Number: 104

Incidence Of Osteoporotic Hip Fractures In Estonia Between 2005 and 2012
Abstract Number: 2679

Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication Use
Abstract Number: 2682

Incidence Trends and Predictors Of Orthopedic Surgery In Patients With Rheumatoid Arthritis – Results From a Well Defined Population
Abstract Number: 970

Incorporating The Health Literacy Universal Precautions Toolkit Quick Start In Academic Rheumatology Practices: Carolina Fellows Collaborative
Abstract Number: 609

Increased Arterial Stiffness In Systemic Lupus Erythematosus (SLE) Patients At Low Risk For Cardiovascular Disease: A Cross-Sectional Controlled Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].